This study is a phase 2, multi-site, prospective, randomized, placebo-controlled, three-arm [two arms double-blinded, one arm evaluator-blinded (participant is aware of his/her treatment status, but evaluator is not)] trial of VIB4920 in 104 adults with seropositive Rheumatoid arthritis (RA) in the United States. Individuals will be eligible if they have moderate or high disease activity (Simplified Disease Activity Index [SDAI] ≥ 17) despite treatment with a TNFi (etanercept or adalimumab) for at least 12 weeks.~Study participation is divided into two phases: the study drug administration period (from week 0 to week 12) and the post-administration observation period (from week 12 to week 40).~Participants will be randomized into one of the following three study arms to assess the efficacy of adding VIB4920 to background disease modifying RA therapy including TNFi and replacing TNFi with VIB4920, as well as the safety of this combination of biologic agents compared to either agent alone.
Patients with moderately-to-highly active Rheumatoid arthritis receive a 12-week VIB4920 treatment with Tumor necrosis factor alpha inhibitor (TNFi) compared to background disease-modifying (RA) therapy with TNFi and without the addition of VIB4920. The primary objective is to determine if the addition of a 12-week course of treatment with VIB4920 to a TNFi in patients with RA who have had an inadequate response to a TNFi results in improved clinical disease control.